INUS
Straddle Chart

Markets / Mutual funds / Sectoral / Thematic

Mutual fundsSIF

Nippon India Pharma Fund - Regular Plan - IDCW

NAVs of 8 Nov 2026

Nippon India Mutual Fund · Equity fund · Regular plan · IDCW

Sectoral / ThematicRegular · IDCWRisk: Very High
NAV · 6 Nov 2026
₹574.0981 ▲ 0.91%
Nippon India Mutual Fund
Fund size₹9,272 crJuly - September 2026
1-month range₹524.86 – 574.10
1 year+11.70%
3 years+18.31%a year
5 years+13.93%a year

What the fund does

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.

BenchmarkBSE Healthcare TRI
Launched5 Jun 2004
Fund houseNippon India Mutual Fund
Fund managersSailesh Raj Bhan

NAV history

527553579 2026-08-122026-08-252026-09-072026-09-212026-10-052026-10-162026-10-30

Returns

1 week
+3.40%avg 5.4%
1 month
+3.35%avg 2.9%
3 months
+0.54%avg -1.9%
6 months
+6.74%avg 3.1%
This year
+12.68%avg 3.2%
1 year
+11.70%avg 3.7%
3 years (a year)
+18.31%avg 13.8%
5 years (a year)
+13.93%avg 11.8%

Bars: this plan; the thin mark is the Sectoral / Thematic average (regular plans, growth option). Over a year: yearly averages (CAGR). Past returns do not guarantee future returns. Information only, not investment advice.

Monthly returns (%)

YearJanFebMarAprMayJunJulAugSepOctNovDec
2024+1.8
2025-7.6-5.9+6.5+2.5+2.2+2.7+2.3-4.1-2.0+2.8+1.6-2.0
2026-4.3+5.7-4.9+5.6+3.1+4.5+2.2+2.0-3.6-0.8+3.4

Each month's change in NAV (the current month to the latest NAV).

What if you had invested?

Worked out from this plan's actual NAVs. SIP: invested on the first NAV of each month. Taxes and exit loads are not included. Past returns do not guarantee future returns. Information only, not investment advice.

Portfolio as on 30 Sept 2026

Stocks held3639 lines in all
Top 10 stocks56.4%of the fund
Short positions-0.1%sold through derivatives
Net equity97.2%long stocks and derivatives minus shorts

Where the money is

Equity 97.3%Cash & others 2.7%Short -0.1%

Sectors (stocks held)

Pharmaceuticals & Biotechnology
74.0%
Healthcare Services
20.3%
Retailing
2.5%
Healthcare Equipment & Supplies
0.5%

Changes since 31 Aug 2026

Share of fund30 Sept 202631 Aug 2026Change
Stocks held97.3%98.0%-0.68
Short positions-0.1%-0.1%0.00
Cash & others2.7%2.0%+0.68
Top 10 stocks56.4%56.8%-0.43
Number of stocks36360
Bought more 2
  • Dr. Reddy's Laboratories Limited+0.52
  • Mankind Pharma Limited+0.29
Cut back 3
  • Sun Pharmaceutical Industries Limited-0.66
  • Lupin Limited-0.26
  • Apollo Hospitals Enterprise Limited-0.26

Change is in percentage points. Bought more and cut back list stocks whose share of the fund moved by at least 0.25 points. A share can also move because the price changed, not only because the fund traded.

Stocks held 36

HoldingSector / type% of fund
Sun Pharmaceutical Industries Limited
INE044A01036		Pharmaceuticals & Biotechnology11.71%
Divi's Laboratories Limited
INE361B01024		Pharmaceuticals & Biotechnology7.10%
Lupin Limited
INE326A01037		Pharmaceuticals & Biotechnology6.17%
Cipla Limited
INE059A01026		Pharmaceuticals & Biotechnology6.01%
Dr. Reddy's Laboratories Limited
INE089A01031		Pharmaceuticals & Biotechnology5.45%
Apollo Hospitals Enterprise Limited
INE437A01024		Healthcare Services4.89%
Mankind Pharma Limited
INE634S01028		Pharmaceuticals & Biotechnology4.38%
Sai Life Sciences Limited
INE570L01029		Pharmaceuticals & Biotechnology3.92%
Ajanta Pharma Limited
INE031B01049		Pharmaceuticals & Biotechnology3.61%
GlaxoSmithKline Pharmaceuticals Limited
INE159A01016		Pharmaceuticals & Biotechnology3.11%
IPCA Laboratories Limited
INE571A01038		Pharmaceuticals & Biotechnology2.87%
Max Healthcare Institute Limited
INE027H01010		Healthcare Services2.70%
Vijaya Diagnostic Centre Limited
INE043W01024		Healthcare Services2.62%
Gland Pharma Limited
INE068V01023		Pharmaceuticals & Biotechnology2.53%
MedPlus Health Services Limited
INE804L01022		Retailing2.53%
Abbott India Limited
INE358A01014		Pharmaceuticals & Biotechnology2.32%
Thyrocare Technologies Limited
INE594H01019		Healthcare Services2.24%
Piramal Pharma Limited
INE0DK501011		Pharmaceuticals & Biotechnology2.24%
Dr. Lal Path Labs Limited
INE600L01024		Healthcare Services2.17%
Alkem Laboratories Limited
INE540L01014		Pharmaceuticals & Biotechnology1.82%
Aurobindo Pharma Limited
INE406A01037		Pharmaceuticals & Biotechnology1.65%
Narayana Hrudayalaya Limited
INE410P01011		Healthcare Services1.61%
Suraksha Diagnostic Limited
INE877V01027		Healthcare Services1.51%
Syngene International Limited
INE398R01022		Healthcare Services1.40%
Emcure Pharmaceuticals Limited
INE168P01015		Pharmaceuticals & Biotechnology1.36%
Pfizer Limited
INE182A01018		Pharmaceuticals & Biotechnology1.35%
Akums Drugs and Pharmaceuticals Limited
INE09XN01023		Pharmaceuticals & Biotechnology1.21%
Anthem Biosciences Limited
INE0CZ201020		Pharmaceuticals & Biotechnology1.19%
Fortis Healthcare Limited
INE061F01013		Healthcare Services1.13%
Biocon Limited
INE376G01013		Pharmaceuticals & Biotechnology1.01%
Sanofi India Limited
INE058A01010		Pharmaceuticals & Biotechnology1.00%
Sanofi Consumer Healthcare India Limited
INE0UOS01011		Pharmaceuticals & Biotechnology0.89%
Molbio Diagnostics Limited
INE869T01028		Healthcare Equipment & Supplies0.54%
Indoco Remedies Limited
INE873D01024		Pharmaceuticals & Biotechnology0.48%
AstraZeneca Pharma India Limited
INE203A01020		Pharmaceuticals & Biotechnology0.42%
Concord Biotech Limited
INE338H01029		Pharmaceuticals & Biotechnology0.17%

Short positions 1

HoldingSector / type% of fund
Net Current Assets–-0.14%

Debt, money market and cash 2

HoldingSector / type% of fund
Triparty Repo–2.81%
Cash Margin - CCIL–0.02%

From the fund house's monthly portfolio (mf.nipponindiaim.com), as on 30 Sept 2026. Percentages are of the fund's net assets; short positions are negative. Published about ten days after each month ends.

Risk

Volatility12.3%yearly, from daily NAVs
Worst fall-17.23%31 Aug 2021 → 30 Jun 2022
RiskometerVery HighVery High

Volatility: how much the NAV moves, as a yearly figure (higher = bumpier). Worst fall: the biggest drop from a high, in the NAV history we hold (from 31 May 2016).

Fund details

Fund size (average AUM, July - September 2026)₹9,272 cr across all plans · this plan ₹7.78 cr
Fund houseNippon India Mutual Fund
CategoryEquity · Sectoral / Thematic
PlanRegular
OptionIDCW
Exit load1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
Minimum investment₹5,000 · additional ₹1,000
Scheme code (AMFI)102432
ISININF204K01950
NAV date6 Nov 2026

Scheme details from the fund's scheme summary document filed with AMFI; expense ratios from AMFI's daily filings.

Other plans of this fund

PlanNAV1 year
Direct · Growth₹646.8090+12.68%
Direct · IDCW₹177.0179+4.43%
Direct · IDCW₹646.8090+12.68%
Regular · Growth₹574.0981+11.70%
Regular · IDCW₹123.9731+3.49%

Top Sectoral / Thematic funds (regular plans)

Fund1 year3 years (a year)
Nippon India Taiwan Equity Fund+37.70%+40.44%
HDFC Defence Fund+19.63%+33.69%
HDFC Pharma and Healthcare Fund+26.81%+30.17%
SBI HEALTHCARE OPPORTUNITIES FUND+21.11%+24.39%
HDFC Transportation and Logistics Fund+8.74%+23.82%
UTI - Healthcare Fund+17.70%+23.50%
Mirae Asset Healthcare Fund+22.57%+23.40%
BANK OF INDIA MANUFACTURING & INFRASTRUCTURE FUND+16.15%+22.19%

All Sectoral / Thematic funds ranked › · Compare with others ›

← All mutual funds

Information only, not investment advice.

What is the NAV of Nippon India Pharma Fund - Regular Plan - IDCW today?

₹574.0981 as of 6 Nov 2026, from AMFI's official NAV data.

What are the returns of Nippon India Pharma Fund - Regular Plan - IDCW?

1 year: 11.70%, 3 years: 18.31% a year, 5 years: 13.93% a year

What is the difference between direct and regular plans?

Both invest in the same portfolio. Direct plans are bought straight from the fund house and pay no distributor commission, so their expenses are lower and their NAV grows slightly faster.